Erytech Pharma strengthens its intellectual property position in the US
Wednesday, April 22, 2015
Erytech strengthens its intellectual property position in the US
Patent covering ERY-ASP in pancreatic cancer granted in US
Term of core encapsulation patent further extended until 2030
It covers use of ERY-ASP1, Erytech`s lead product, for treatment of pancreatic cancer (currently in phase II clinical trial)
reuters.com
